Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (20761)	12/6/2006 11:02:55 AM
From: ACAN	Respond to of 23958

Ray; Prechter got me worried last night, but very interesting long term comparisons of relative values, stocks, gold, debt and some scary inverse relationships about irrational exuberance re money in the market compared to previous tops

To: Galirayo who wrote (20761)	12/6/2006 11:12:48 AM
From: ACAN	Read Replies (1) \| Respond to of 23958

Ray; [CNXT] back over support on good volume stockcharts.com

To: Galirayo who wrote (20761)	12/6/2006 11:35:49 AM
From: ACAN	Read Replies (1) \| Respond to of 23958

Ray; [GNBT] Generex Biotechnology Receives 2006 North American Frost & Sullivan Award for Technology Innovation Wednesday December 6, 11:09 am ET Award Recognizes Generex Oral-lyn(TM) TORONTO--(MARKET WIRE)--Dec 6, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been awarded the 2006 North American Frost & Sullivan Award for Technology Innovation for its proprietary oral insulin spray product, Generex Oral-lyn. ADVERTISEMENT Frost & Sullivan's Technology Innovation Award is bestowed upon a company (or individual) that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. This award recognizes the quality and depth of a company's research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor. In bestowing the award on Generex Oral-lyn, Frost & Sullivan stated that the product "is strongly positioned to be the most acceptable form of alternative, needle-free insulin delivery to patients and doctors alike as there is a huge global demand for prandial glucose control, which is emerging as a key factor in reducing cardiovascular risk. By totally eliminating pain and increasing patient convenience and treatment compliance, Generex Oral-lyn is expected to improve the quality of life of diabetic patients with a relative decrease in diabetic complications and a significant reduction in the enormous costs associated with insulin therapies." Frost & Sullivan further stated that "by applying its innovative buccal drug delivery technology Generex is highly focused toward the commercialization of a novel and painless oral insulin therapy, which is sure to revolutionize the insulin market. The company, with its committed research and development of the highly unique insulin product that is safe, simple to deliver, fast in action and that offers high flexibility to the patient and the physician, has already got market attention, which takes the company on a further commercial stand." Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.